A Randomized, Double-Masked, Sham-Controlled Clinical Trial of Intravitreal Faricimab for Chronic Central Serous Chorioretinopathy With or Without Secondary Macular Neovascularization: Study Protocol for a Randomised, Double-Masked Trial

Dysregulation of the Angiopoietin-2 (Ang-2)/Tyrosine kinase with Immunoglobulin-like and EGF-like domains 2 (Tie-2) signaling pathway has been implicated in choroidal vascular instability and RPE dysfunction in Central serous chorioretinopathy (CSCR) and pachychoroid-associated neovascularization.
This study prospectively evaluates the efficacy and safety of faricimab compared to sham in CSCR with and without secondary neovascularization, using standardized anatomical and functional endpoints. The results of this trial may help define the role of dual pathway inhibition in CSCR and inform future treatment strategies for this challenging and vision threatening condition.

Start Date01 Dec 2026

Sponsor / Collaborator

Singapore National Eye Centre Pte Ltd.

NCT07695298

/ RecruitingPhase 4IIT

A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome [PLANE Study]

This study will evaluate the safety and effects, good or bad of faricimab (Vabysmo®), a drug that is approved by the U.S. Food and Drug Administration (FDA) for other retinal conditions, but its use is considered investigational when used specifically for choroidal neovascularization (CNV) related to presumed ocular histoplasmosis (POHS)

Start Date01 Jul 2026

Sponsor / Collaborator

Cincinnati Eye Institute

[+1]

NCT07367282

/ RecruitingPhase 4IIT

A Phase IV, Prospective, Open-label, Single-arm Clinical Trial to Evaluate the Efficacy of Faricimab and Biomarker Assessment in Patients With Neovascular Age-related Macular Degeneration

If the subject who has nAMD voluntarily agrees to participate in this clinical study by signing the informed consent form, screening assessments will be conducted within 4 weeks prior to the first dose of the investigational drug. During the screening visit, the eligibility of the subject will be assessed and one study eye will be selected. If both eyes are eligible, the eye with the worst best-corrected visual acuity (BCVA) at screening will be chosen. However, if the investigator determines that the other eye requires more urgent treatment for clinical reasons, that eye may be selected as the study eye.
After screening assessments and evaluation based on inclusion/exclusion criteria, eligible subjects will be enrolled. Vabysmo® 6 mg (0.05 mL) will be administered via intravitreal injection every 4 weeks (monthly) for a total of 4 doses during the initial loading period. After the loading dose, patients will undergo disease activity assessment based on imaging and visual acuity (VA) outcomes followed by the IP administration at Week 20. The treatment interval will be determined based on disease activity assessed at Week 20, depending on the results, the subsequent administration may be scheduled at Week 28 or Week 32, at the investigator's discretion. Thereafter, the dosing interval may be further adjusted in 4-week increments, either extended or shortened, according to imaging and visual outcomes.
Throughout the clinical study, patients will need to visit the study site at least 10 times, including the screening visit. The number of intravitreal injections administered will be 4 doses during the initial loading period and up to 5 doses during the treat-and-extend (T&E) period (Weeks 20, 28, 36, 44, 52). Thus, the total number of injections during the study will range from a minimum of 7 to a maximum of 9 injections.
If the non-study eye also has nAMD, treatment with a locally approved therapy may be administered outside the scope of this study.

Start Date29 Jun 2026

Sponsor / Collaborator

Asan Medical Center

100 Clinical Results associated with Faricimab

100 Translational Medicine associated with Faricimab

100 Patents (Medical) associated with Faricimab

580

Literatures (Medical) associated with Faricimab

02 Jul 2026·INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE

Aflibercept and Faricimab Equipotently Restore Endothelial Barrier Function

Article

Author: Rao, Martin ; Brunck, Lynne ; Lesche, Ralf ; Lange, Claudia ; Prinz, Florian ; Strunz, Tobias ; Toedling, Joern ; Mielke, Johanna ; Tetzner, Reimo

Purpose:

To study the biological effects of aflibercept and faricimab on vascular endothelial growth factor (VEGF)-A165-induced vascular permeability in an in vitro head-to-head comparison using human-derived endothelial cells.

Methods:

This in vitro study used a human umbilical vein endothelial cell (HUVEC)-based model, in which cells were exposed to VEGF-A165, followed by the addition of aflibercept (1.7 nM) or faricimab (2.0 nM) either simultaneously (preventive) or 24 hours later (therapeutic/rescue). Cell-layer permeability was measured on the xCELLigence platform, global transcriptomic changes by RNA sequencing, and VEGF-A165-induced release of angiogenesis-related proteins by electrochemiluminescence immunoassay.

Results:

Concurrent addition of aflibercept or faricimab prevented VEGF-A165-triggered increase of HUVEC cell-layer permeability (P = 0.0005). In the therapeutic/rescue setting, either drug temporally improved the cell-layer integrity (P = 0.0001). Aflibercept was non-inferior to faricimab in both the preventive (P < 0.0001) and therapeutic/rescue (P < 0.0001) settings. Aflibercept and faricimab comparably downregulated VEGF-A165-induced angiogenesis-related genes. Aflibercept and faricimab equipotently suppressed or reversed VEGF-A165 upregulation of ANGPT2 gene expression and angiopoietin-2 (ANG2) protein in culture supernatant. VEGF-A165-driven TEK gene expression and soluble Tie2 increase in culture supernatant was reversed with aflibercept and faricimab in both settings.

Conclusions:

In this in vitro model of VEGF-A165-driven vascular permeability, additional blockade of ANG2 with faricimab did not improve endothelial barrier integrity beyond VEGF-A165 blockade alone with aflibercept, despite significant upregulation of ANG2 expression after VEGF-A165 stimulation. Aflibercept and faricimab were comparable in maintaining or restoring endothelial barrier function and thereby vascular integrity, mainly attributable to inhibition of VEGF-A165 binding to its receptor.

01 Jul 2026·Ophthalmology and Therapy

Functional Real-World Outcomes of Aflibercept 8 mg Versus Faricimab After Loading Phase in Diabetic Macular Edema

Article

Author: Baldascino, Antonio ; Lupo, Stefano ; Guillot, Antonio ; De Luca, Laura ; Calabro, Mattia ; Meduri, Alessandro ; Vingolo, Enzo Maria ; Menna, Feliciana

INTRODUCTION:

Aflibercept 8 mg and faricimab provide effective anatomical and visual acuity improvements in diabetic macular edema (DME), although functional recovery may not be fully captured by conventional endpoints. Microperimetry offers a sensitive and spatially resolved assessment of macular function and may better reflect early neurosensory changes.

METHODS:

This real-world, retrospective comparative cohort study included 60 treatment-naïve eyes of 60 patients with center-involving DME treated at Ospedale Fiorini di Terracina. Thirty eyes received intravitreal aflibercept 8 mg and 30 eyes received intravitreal faricimab 6 mg as three consecutive monthly injections. Outcomes included best-corrected visual acuity (BCVA), central retinal thickness (CRT) measured by spectral-domain optical coherence tomography, and mean retinal sensitivity (RS) assessed using Nidek MP-3 microperimetry. Statistical analyses included paired and unpaired t tests, repeated-measures analysis of variance, odds ratios (OR) for achieving a ≥ 3 dB RS gain, and Pearson correlation analyses.

RESULTS:

Both treatments significantly improved BCVA and CRT after the loading phase, with slightly greater improvements observed in the faricimab group, although not statistically significant. Mean CRT reduction was - 122 ± 47 µm with aflibercept 8 mg and - 138 ± 52 µm with faricimab (p = 0.21). BCVA improved by + 5.8 ± 4.9 and + 7.2 ± 5.4 letters, respectively (p = 0.17). Retinal sensitivity increased in both groups, with a greater gain observed with faricimab (+ 4.8 ± 1.9 dB) compared with aflibercept (+ 2.1 ± 1.6 dB; p < 0.001). Faricimab-treated eyes were more likely to achieve a ≥ 3 dB RS improvement (OR 3.2; 95% CI 1.4-7.6). RS improvement correlated with CRT reduction (r = 0.42) and BCVA gain (r = 0.57).

CONCLUSION:

Despite similar anatomical and visual acuity outcomes, faricimab was associated with greater short-term improvement in retinal sensitivity compared with aflibercept 8 mg during the loading phase. These findings support microperimetry as a sensitive functional endpoint in DME research and selected clinical settings.

01 Jul 2026·Ophthalmology and Therapy

Real-World Outcomes After Switching to Faricimab in Patients with Chronic Diabetic Macular Edema at a Tertiary Eye Center in Singapore

Article

Author: Fukutsu, Kanae ; Cheung, Gemmy C M ; Tan, Gavin S W ; Ong, Charles ; Zheng, Fang ; Tan, Anna C S ; Goh, Rose Ann

INTRODUCTION:

To evaluate visual and anatomical outcomes after switching to faricimab in Singaporean patients with diabetic macular edema (DME) previously treated with other anti‑vascular endothelial growth factor (VEGF) agents or therapies.

METHODS:

This was a retrospective single-center cohort study with chart review. The subjects were patients with DME at the Singapore National Eye Centre who had a suboptimal response to prior therapy and therefore switched to faricimab between 2022 and 2024; all received three or four consecutive intravitreal faricimab injections on the basis of the treating physician's clinical decision. We analyzed changes in best available visual acuity (BAVA; ETDRS letters) and central subfield thickness (CST) on optical coherence tomography (OCT) from baseline to the first follow-up after the loading of faricimab. The initial loading regimen, consisting of three or four consecutive intravitreal faricimab injections, was determined by the treating clinician. We also conducted a subgroup analysis comparing outcomes between the three-injection and four-injection groups.

RESULTS:

A total of 157 eyes from 131 patients were included, comprising 101 eyes in the three-injection group and 56 eyes in the four-injection group. The median duration of prior therapy was 1.8 years (interquartile range [IQR] 3.6). Mean BAVA improved significantly from 57.8 ± 16.5 to 62.4 ± 15.0 ETDRS letters at mean final follow-up of 6.9 weeks (p < 0.001). Mean CST decreased from 431.4 ± 129.4 µm to 334.2 ± 90 µm (p < 0.001). No significant differences in BAVA change (p = 0.39) or CST change (p = 0.58) were observed between the three‑ and four‑injection groups.

CONCLUSION:

Switching to faricimab resulted in significant short-term improvements in both visual acuity and retinal thickness even among patients with chronic DME who were previously receiving long-term treatment.

347

News (Medical) associated with Faricimab

27 Jul 2026

·www.biopharmadive.com

FDA scientists question Capricor data; Legend CEO steps down

Today, a brief rundown of news involving Capricor Therapeutics and Legend Biotech, as well as updates from AstraZeneca, Outlook Therapeutics and Otsuka Pharmaceutical that you may have missed.Capricor Therapeutics shares lost nearly two-thirds of their value on Monday after briefing documents indicated that Food and Drug Administration staff reviewers are highly critical of the data supporting the companys experimental cell therapy for Duchenne muscular dystrophy. The FDA previously turned back that cell therapy, deramiocel, but accepted a new application and scheduled a July 29 advisory committee meeting after the company accumulated new data. In documents filed ahead of the panel, FDA scientists noted that Capricors therapy missed its initial Phase 3 study goals, and that its final application included statistical analyses the agency hadnt agreed to. Those changes were unwarranted based on the studys design, powering, and original statistical assumptions, agency reviewers wrote. Capricors findings may have also been compromised by functional unblinding given a distinctive difference in the adverse events observed among drug and placebo recipients, they added.Legend Biotech CEO Ying Huang has stepped down as part of a leadership transition, the cell therapy developer said Friday. Huang has led Legend over the last seven years, during which time the company helped bring the Johnson & Johnson-partnered multiple myeloma treatment Carvykti to market and established a competitive position in in vivo cell therapy development. Still, company shares have lost about half their value over the last year amid crowding competition in multiple myeloma. Alan Bash, the head of Legends Carvykti business unit, will serve as interim CEO while the board searches for a full-time replacement.The incoming CEO, and their interactions/board alignment, will be critical to turning the story around, wrote Oppenheimer analyst Kostas Biliouris, in a Monday note to clients.A few weeks after disclosing a major research setback, AstraZenecahas reported mixed results in two more late-stage readouts. In one Monday announcement, the company revealed its rare disease drug Ultomiris failed a Phase 3 trial in a rare complication related to stem cell transplants. AstraZeneca also said that its antibody-drug conjugate sonesitatug vedotin meaningfully improved survivalwhen compared to standard treatment options in patients with certain gastric cancers, but missed statistical significance on a measure of tumor progression. The former readout erases a potential expansion opportunity for a drug AstraZeneca acquired from Alexion Pharmaceutical and that generated about $2.6 billion in sales between January and June. The latter could still give AstraZeneca a chance to gain an approval for an ADC it licensed in a 2023 deal. Itll share the results with global health authorities.The FDA on Friday finally cleared for use a treatment Outlook Therapeutics developed for a form of age-related vision loss. That medicine, Lytenava, is a version of bevacizumab the active ingredient in Avastin Outlook formulated as an eye drop for the wet form of age-related macular degeneration. Injectable Avastin is widely used off-label to treat wet AMD along with other drugs like Eylea and Vabysmo. Outlook said Lytenava is the first purpose-built ophthalmic formulation of bevacizumab and, while its been approved in Europe and the U.K. for multiple years, it was previously rejected by U.S. regulators three times. Outlook appealed the last rejection and was able to convince the agency earlier this year to change its position.The FDA on Friday also approved a new medicine for attention deficit hyperactive disorder, or ADHD. Called Simtriyo and developed by Otsuka Pharmaceutical, the drug is the first marketed medicine of its kind, targeting three brain chemicals norepinephrine, dopamine and serotonin instead of two, like Adderall or Ritalin. Otsuka said the therapy should be available later this year. '

Phase 3Drug ApprovalCell TherapyClinical ResultExecutive Change

27 Jul 2026

·www.pharmaceutical-technology.com

Outlook Therapeutics wins FDA approval for Lytenava in wet AMD

Wet AMD is an eye disorder characterised by leaky vessels in the retina causing vision loss. Credit: PeopleImages/Shutterstock.com. Following years of regulatory setbacks that saw multiple rejections, Outlook Therapeutics has secured US Food and Drug Administration (FDA) approval for eye disease drug Lytenava (bevacizumab). Outlook’s Lytenava is approved for treatment of neovascular age-related macular degeneration (nAMD), commonly known as wet AMD. The drug is administered by intravitreal injection. Bevacizumab is already a commonly used first-line off-label treatment option for wet AMD, owing to its anti-vascular endothelial growth factor (anti-VEGF) action, which blocks a protein that causes leaky blood vessels. Bevacizumab was originally developed by Roche’s Genentech as an anti-cancer therapy under the brand name Avastin and is normally administered by intravenous injection. Outlook says that, for the first time, retina specialists and patients have access to an FDA-approved ophthalmic bevacizumab developed specifically for the eye. Wet AMD is an eye disorder characterised by the growth of abnormal vessels in the macula. These leak blood or fluid, which leads to a rapid loss of vision. Outlook’s CEO Bob Jahr commented: “Rather than relying on repackaged formulations originally intended for intravenous use, physicians now have access to a purpose-built ophthalmic formulation of bevacizumab designed specifically for intravitreal administration that delivers the manufacturing consistency, product quality, and regulatory oversight patients deserve.” Outlook stated it is executing the commercial launch for Lytenava, with availability for eligible US patients set to start before the end of 2026. While Lytenava is already approved in Europe and the UK, FDA approval for the injection means Outlook has its first commercial product in the US. It has been far from a straightforward journey to this milestone. The US biotech was on the receiving end of three complete response letters (CRLs) from the FDA since a first regulatory submission to the agency in 2022. The central underlying qualm from the agency was a lack of substantial evidence of effectiveness , which Outlook contested. Following the third CRL, Outlook filed a formal dispute resolution request in April 2026. The FDA Office of New Drugs granted the appeal a month later, agreeing that substantial evidence of effectiveness had in fact been met. With marketing authorisation granted, Outlook joins a competitive wet AMD market. While it has gone through significant shifts in recent years, it is still dominated by anti-VEGF drugs. Bayer and Regeneron’s Eylea (aflibercept) has long dominated the global wet AMD market, netting nearly $8bn in sales in 2025. However, Eylea is undergoing patent expiries, opening the door for Roche’s Vabysmo (faricimab) – also an anti-VEGF medication – to gain market share . Outlook places the value of the US anti-VEGF retina market alone at approximately $8.5bn. Analysis by GlobalData’s Pharma Intelligence Center forecasts it will rise to $13.8bn in 2033. GlobalData is the parent company of Pharmaceutical Technology .

Drug ApprovalPatent InfringementPatent Expiration

23 Jul 2026

·www.fiercepharma.com

Roche defends 6B franc Vabysmo peak sales target despite another quarterly miss

Roche’s Vabysmo disappointed investors again. In the second quarter, the eye drug’s sales of about 1.04 billion Swiss francs ($1.27 billion) missed analysts’ expectations by 7.1%. Speaking on an investor call Thursday, Roche Pharmaceuticals CEO Teresa Graham assured analysts that the U.S. branded market has stabilized after a period of contraction, though the explosive growth that Vabysmo enjoyed early in its launch is likely behind it. “We are seeing that 2% to 3% growth in the overall retinal market,” Graham said. “We do expect that this is going to be the new normal, and we don’t expect a rebound to previous levels.” Vabysmo’s Q2 sales figure represents a 1% decline year over year. But Roche expects the drug’s revenue in the U.S. to grow by a low- to mid-single-digit for the full year, and its global sales to increase by low double-digits, according to Graham. “We continue to consider consensus peak sales expectations for Vabysmo of around 6 billion [Swiss francs], it’s very reasonable, and we’re confident that we’re on track to achieve this number,” Graham said. Initially approved by the FDA in early 2022, Vabysmo started to show signs of a deceleration toward the latter half of 2025, partly thanks to the closure of certain copay assistance programs. The first biosimilar to a key rival drug, Regeneron’s Eylea, was also launched toward the end of 2024. Graham stressed that the Eylea biosimilar didn’t impact Vabysmo. In the ophthalmology space, biosimilars tend to only affect the originators that they reference, without much bleed-over to other products, she observed. Citing physician surveys, Graham noted that Vabysmo is a physicians’ favorite and therefore expects it to “take a disproportionate share” of the overall branded market growth. Beyond Vabysmo, immunology drug Xolair was cited as the biggest growth driver in Roche’s pharma business. In Q2, Xolair’s sales jumped 21% year over year, reaching 965 million Swiss francs ($1.18 billion) while crushing Wall Street consensus by 10.5%. A slowdown could be around the corner. Roche currently projects a September entry for the first Xolair biosimilar in the U.S. But the Swiss pharma is still guiding to roughly 20% growth for the entire year of 2026. Elsewhere in the immunology department, Graham expressed excitement over the potential of Gazyva—a CD20 antibody initially utilized as a cancer therapy—in autoimmune indications. Despite continued competitive pressure in the chronic lymphocytic leukemia field pulling back Gazyva to flat sales year over year, Graham cited “first early indications” of its launch progress in lupus nephritis. In the U.S., Germany and the U.K., where Gazyva is available in lupus, Roche recorded Gazyva quarterly sales growth with patient share approaching 10%, according to Graham. Roche expects FDA decisions on three Gazyva label expansion opportunities this year, including idiopathic nephrotic syndrome on Sept. 27, membranous nephropathy on Nov. 15 and systemic lupus erythematosus (SLE) on Dec. 4. With all of Gazyva’s immunology indications filed with the FDA, Roche expects that they will fuel its 2 billion Swiss francs peak sales ambition. In Q2, Gazyva sales of 242 million Swiss francs missed consensus by 8.4%. In lupus, Roche has stopped development of a CD19xCD3 bispecific after evaluating the drug in a phase 1 SLE trial. Simultaneously, the company has moved Lunsumio, a CD20xCD3 T-cell engager approved for blood cancer treatment, into phase 2 testing for SLE. “SLE is a very heterogeneous and complex disease,” Graham explained on the Q2 call. “While we saw great results with Gazyva, we do believe there’s an opportunity for more benefit for patients, and based on Lunsumio’s mechanism of action and its safety profile, we think it could actually be a really great option for patients with SLE.” Overall, Roche’s 12.16 billion Swiss francs in pharmaceutical sales came 1.3% ahead of consensus, boosting group-wide sales to 15.5 billion Swiss francs during Q2.

Drug ApprovalPhase 2Phase 1BiosimilarImmunotherapy

100 Deals associated with Faricimab

External Link

KEGG	Wiki	ATC	Drug Bank
D11516	Faricimab	-	DB15303

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Angioid Streaks	Japan	Chugai Pharmaceutical Co., Ltd.	19 May 2025
Retinal vein occlusion-related macular edema	Australia	Roche Products Pty Ltd.	08 Aug 2022
Age Related Macular Degeneration	Japan	Chugai Pharmaceutical Co., Ltd.	28 Mar 2022
Choroidal Neovascularization	Japan	Chugai Pharmaceutical Co., Ltd.	28 Mar 2022
Dystrophy, Macular	Japan	Chugai Pharmaceutical Co., Ltd.	28 Mar 2022
Diabetic macular oedema	United States	Genentech, Inc.	28 Jan 2022
Wet age-related macular degeneration	United States	Genentech, Inc.	28 Jan 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Retinal Vein Occlusion	NDA/BLA	United States	Roche Holding AG	09 May 2023
Proliferative retinopathy with diabetes mellitus	Phase 3	United States	Genentech, Inc.	04 Aug 2025
Myopic choroidal neovascularization	Phase 3	China	F. Hoffmann-La Roche Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	China	Roche China Holding Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	Australia	F. Hoffmann-La Roche Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	Australia	Roche China Holding Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	France	Roche China Holding Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	France	F. Hoffmann-La Roche Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	Germany	Roche China Holding Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	Germany	F. Hoffmann-La Roche Ltd.	28 Feb 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03823287 \| NCT03823300 (TENAYA, Pubmed \| Ophthalmol Sci)	Phase 3	Wet age-related macular degeneration	1,329	Faricimab 6 mg	hggeszxqxz(rnmfhukmvg) = zrjxxxuhll hsxcloqqyl (uudsdbenmq ) View more	Positive	01 May 2026
NCT03823287 \| NCT03823300 (TENAYA, Pubmed \| Ophthalmol Sci)	Phase 3	Wet age-related macular degeneration	1,329	Aflibercept 2 mg	hggeszxqxz(rnmfhukmvg) = caztgxjfzz hsxcloqqyl (uudsdbenmq ) View more	Positive	01 May 2026
ALTIMETER (Pubmed \| Ophthalmol Sci)	Phase 2	Diabetic macular oedema	99	Faricimab 6.0 mg	hqvilrtzxi(gxqlthyqzm) = iasodisnxo qwyhtormkj (qnjcsubgap, 7.5 - 10.9) View more	Positive	01 May 2026
NCT03622593 (RHINE, Pubmed \| Ophthalmol Ther)	Phase 3	Diabetic macular oedema	152	Faricimab 6.0 mg every 8 weeks (Q8W)	pqvgjsxbas(toeksdgaoe) = bmjszlhqnc vxpfdyhfze (fwyqajhrgi )	Positive	10 Apr 2026
NCT03622593 (RHINE, Pubmed \| Ophthalmol Ther)	Phase 3	Diabetic macular oedema	152	Faricimab 6.0 mg treat-and-extend (T&E)	pqvgjsxbas(toeksdgaoe) = kmsurlhwxy vxpfdyhfze (fwyqajhrgi )	Positive	10 Apr 2026
APAO2026	Not Applicable	-	159	Aflibercept 8 mg	-	Positive	18 Feb 2026
APAO2026	Not Applicable	-	159	Faricimab	lkmkmislyu(qzxzmhcglo) = mamzykcqbf mlsnmfmwvy (jrlshmoyci )	Positive	18 Feb 2026
APAO2026	Not Applicable	Retinal Diseases	80	Faricimab	mxdamvlelm(bnjnquonxu) = wgwopzkznb eylsjpvnaa (ftkilqoshv ) View more	Positive	18 Feb 2026
APAO2026	Not Applicable	Diabetic macular oedema \| Retinal Vein Occlusion	128	Faricimab	xgpreamgre(sqxbzoafiv) = no significant ocular or systemic adverse events were observed in all groups. zepyupftgs (cusdhkwdkh ) View more	Positive	18 Feb 2026
APAO2026	Not Applicable	Diabetic macular oedema \| Retinal Vein Occlusion	128	Ranibizumab		Positive	18 Feb 2026
APAO2026	Not Applicable	Wet age-related macular degeneration	57	Faricimab	dskyrqfxkq(wizgmnajzb) = oedoudvthi ubhezyebrj (xcxiuvsbll ) View more	Positive	18 Feb 2026
APAO2026	Not Applicable	Wet age-related macular degeneration	50	Faricimab 6 mg/0.05 ml (refractory nAMD)	bqqeucaugj(afprzmhbxa) = amlxlldezx ohywgilsct (jhgorgaiks, 0.55) View more	Positive	18 Feb 2026
APAO2026	Not Applicable	Retinal Vein Occlusion	18	Faricimab	gjcdkuuszc(lgpttrkeqw) = tcjgwuywvf nrbnzkyqkh (ayuismgmou, 40 - 81) View more	Positive	18 Feb 2026
APAO2026	Not Applicable	Diabetic macular oedema	11	Faricimab (Diabetic Macular Edema)	ndwpedgbvv(hlnypgdaik) = iuilbidthc yockmhwwbx (zwswysppyp ) View more	Positive	18 Feb 2026

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis